Treating BRAF V600E Colorectal Cancer May Require Concomitant BRAF and PI3K/mTOR Inhibition 

Get Permission

BRAF V600E mutations are associated with poor prognosis in colorectal cancer. A study by Coffee and colleagues examined PI3K/mTOR signaling in BRAF V600E colorectal cancer cell lines after BRAF inhibition as well as cell viability and apoptosis after combined BRAF and PI3K/mTOR inhibition. 

Western blot analysis showed sustained PI3K/mTOR signaling after BRAF inhibition. In a novel genetically engineered mouse model for BRAF V600E colorectal cancer, mice developed sessile serrated adenomas/polyps similar to those in humans. Combination treatment with BRAF and PI3K/mTOR inhibitors resulted in induction of apoptosis and tumor regression.

The investigators stated, “We have established a novel [genetically engineered mouse model] to interrogate BRAFV600E [colorectal cancer] biology and identify more efficacious treatment strategies. Combination BRAF and PI3K/mTOR inhibitor treatment should be explored in clinical trials.” ■

Coffee EM, et al: Clin Cancer Res 19:2688-2698, 2013.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.